Evidence map›Paper›PMID 41305722›Full record

ArticleMedicine2025

Bibliometric analysis of the correlation between aflatoxin and hepatic carcinoma.

Zheng Liu, Bao-Chen Zhu, Chun-Miao Xue, Xin Huang, Ruo-Yu Gao, Wen-Hui Liu, Jiao-Jiao Cheng, Jin-Gui Wang, Zhi-Bin Song, Shi-Xin Chen and 2 more

Abstract read
In one paragraph

Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Zheng LiuDepartment of Pharmacy, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.ORCID 0009-0001-2358-5596
Bao-Chen ZhuDepartment of Pharmacy, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Chun-Miao XueDepartment of Pharmacy, Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Xin HuangDepartment of Respiratory Medicine, Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China.
Ruo-Yu GaoDepartment of Pharmacy, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.
Wen-Hui LiuDepartment of Pharmacy, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.
Jiao-Jiao ChengDepartment of Pharmacy, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Jin-Gui WangDepartment of Pharmacy, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Zhi-Bin SongDepartment of Pharmacy, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Shi-Xin ChenDepartment of Pharmacy, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Dan-Hua ZhaoDepartment of Pharmacy, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Guo-Dong HuaDepartment of Pharmacy, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.

Funding

DZMG-QNHB0003
6 · The paper itself

Abstract

backgroundAflatoxin serves as a distinct risk factor for hepatic carcinoma, making the investigation into its association with hepatic carcinoma is essential for unraveling the molecular underpinnings of oncogenesis and devising therapeutic strategies for tumors. However, the mechanism by which aflatoxin causes liver cancer is not yet clear. This article aims to analyze the latest research progress and cutting-edge exploration directions for aflatoxin-induced liver cancer.

methodThis research relies on the Web of Science core collection for information retrieval, leveraging the broad scope of the SCI-EXPANDED index to guarantee comprehensiveness and high precision of the gathered data. From April 30, 2014 to April 30, 2024, relevant original research literature and reviews on aflatoxin and liver cancer were retrieved. Subsequently, VOSviewer, CiteSpace, and R software were used to visualize and analyze the articles.

resultsA total of 597 relevant studies were obtained, with 3228 authors from 1116 organizations in 94 countries. America and China are major contributors to international publications. Groopman, John D has the most publications, and Jessica Zucman-Rossi has the highest number of citations. Guangxi Medical University, China Agricultural University, Johns Hopkins University, etc were the main research institutions. Toxins, Food and Chemical Toxicology are popular journals in this field, and the most cited journal is Nature Reviews Gastroenterology & Hepatology. Research primarily focuses on 4 areas: the correlation between aflatoxin contamination, exposure levels, and the progression of hepatic carcinoma; the underlying processes by which aflatoxin inflicts liver injury that may result in hepatic carcinoma; the combined impact of aflatoxin B1 and the hepatitis B virus (HBV) on the onset of hepatic carcinoma; and strategies for the prevention and management of aflatoxin-induced hepatic malignancies. Specifically, aflatoxins can induce hepatotoxicity, immunotoxicity, alter expression of coding genes and noncoding RNAs, and synergize with hepatitis B virus to promote hepatocarcinogenesis. Physical, chemical, and biological methods have been widely employed to degrade aflatoxins for liver cancer prevention and control, among which biological control have garnered significant attention from researchers.

conclusionResearch on the aflatoxin-hepatic carcinoma link is rapidly advancing. Furthermore, it confirms aflatoxin's pivotal role in the pathogenesis of liver cancer.

Indexed as

AflatoxinsBibliometricsCarcinoma, HepatocellularLiver NeoplasmsHumansRisk FactorsAflatoxinsaflatoxinbibliometricsliver cancermechanism

Identifiers

PMID41305722
PMCPMC12643785

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.